Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Canakinumab||Ilaris||ACZ-885||Ilaris (canakinumab) is a monoclonal antibody against interleukin-1beta, which has anti-inflammatory activity and may decrease tumor progression (PMID: 28855077).|
|Docetaxel||Taxotere||RP56976||Antimicrotubule Agent 12||Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03626545||Phase III||Canakinumab + Docetaxel Docetaxel||Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)||Active, not recruiting|